Safety
neutropenia, leukopenia, toxicity, anemia, acute kidney injury, hypokalemia
NEUTROPENIA, LEUKOPENIA, INTESTINAL OBSTRUCTION, ADVERSE EVENTS, ANEMIA, EVENTS, URINARY TRACT INFECTION
Hematological toxicity and gastrointestinal events were the most common adverse events (AEs). AEs of Grade ≥ 3 occurred in 65.6 and 62.5% of patients in the Socazolimab + TP and Placebo + TP groups, respectively. The most common AEs included neutropenia (59.4% vs. 56.3% of the two groups, respectively), leukopenia (43.8% vs. 25.0%), hypokalemia (18.8% vs. 0), anemia (12.5% vs. 6.3%), and decreased platelet count (12.5% vs. 6.3%) (Additional File Dosage was reduced for eight patients (25.0%) due to AEs arising during neoadjuvant therapy. The dose reductions of nab-paclitaxel in the Socazolimab + TP and Placebo + TP groups were 15.6 and 18.8%, respectively, and those of cisplatin were 6.3 and 3.1%, respectively. Treatment was terminated for two patients (6.3%) in the Socazolimab + TP group due to a urinary tract infection and an acute kidney injury, while a single patient (3.1%) in the Placebo + TP group was discharged due to an intestinal obstruction.